<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500812</url>
  </required_header>
  <id_info>
    <org_study_id>BA-210-101</org_study_id>
    <nct_id>NCT00500812</nct_id>
    <nct_alias>NCT00104221</nct_alias>
  </id_info>
  <brief_title>A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries</brief_title>
  <official_title>A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, open-label, dose-escalation study designed to evaluate the&#xD;
      safety, tolerability and pharmacokinetics of Cethrin in two types of spinal cord injury&#xD;
      patients: those with a complete cervical injury or a complete thoracic injury. Dose levels&#xD;
      from 0.3 mg - 9 mg of Cethrin will be administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary goal of this study is to determine the safety and tolerability of Cethrin when administered in conjunction with fibrin sealant to the dura mater of the spinal cord.</measure>
    <time_frame>Prestudy, 24-72 hrs, 6 weeks, 3, 6 &amp; 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy by AIS</measure>
    <time_frame>Pre-study, 24-72 hrs, 6 weeks, 3, 6 &amp; 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects Receiving 0.3 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 1 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 3 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 6 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 9 mg Cethrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cethrin</intervention_name>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_label>1 mg</arm_group_label>
    <arm_group_label>3 mg</arm_group_label>
    <arm_group_label>6 mg</arm_group_label>
    <arm_group_label>9 mg</arm_group_label>
    <other_name>(BA-210)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients will be enrolled in this study only if they meet all of the following criteria:&#xD;
&#xD;
          -  Informed Consent Form signed by the patient or patient's legal representative.&#xD;
&#xD;
          -  Male or female, aged 16-70 years, inclusive.&#xD;
&#xD;
          -  For Group 1, patients with acute thoracic (T2-T12) spinal cord injury; for Group 2,&#xD;
             patients with acute cervical (C4-T1) spinal cord injury. The site of surgery should be&#xD;
             able to accommodate a minimum volume of 2 mL of fibrin sealant.&#xD;
&#xD;
          -  Scheduled to undergo spinal decompression surgery or other interventional spinal&#xD;
             surgery (e.g., fixation) within 7 days of injury.&#xD;
&#xD;
          -  ASIA Impairment Scale grade of A (complete, no motor or sensory function present in&#xD;
             the sacral segment) as assessed within 12 hours before surgery.&#xD;
&#xD;
          -  Able to communicate effectively to obtain informed consent and to ensure neurological&#xD;
             examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will not be enrolled in this study if they meet one of the following criteria:&#xD;
&#xD;
          -  Use of any experimental drug, or participation in any clinical trial, within 30 days&#xD;
             prior to surgery.&#xD;
&#xD;
          -  History of adverse reaction to fibrin sealant.&#xD;
&#xD;
          -  History of hypersensitivity to bovine products.&#xD;
&#xD;
          -  Any medical condition that may interfere with the ASIA assessments.&#xD;
&#xD;
          -  Clinically significant neurological, cardiac, respiratory, hepatic, or renal disease&#xD;
             or malignancy.&#xD;
&#xD;
          -  Hemophilia or other bleeding abnormality as defined by:&#xD;
&#xD;
               -  Platelet level lower than 100 X 109/L&#xD;
&#xD;
               -  Activated partial thromboplastin time or international normalized ratio higher&#xD;
                  than the upper limit of normal&#xD;
&#xD;
               -  Baseline hematocrit lower than 0.25&#xD;
&#xD;
          -  Gunshot wound as the presenting injury, or any evidence of transecting injury to the&#xD;
             spinal cord (e.g., by stab wound).&#xD;
&#xD;
          -  Cognitive impairment which may preclude accurate neurological assessments (e.g.&#xD;
             traumatic head injury with GCS of less than or equal to 14).&#xD;
&#xD;
          -  Ankylosing Spondylitis.&#xD;
&#xD;
          -  Diabetes mellitus requiring insulin therapy.&#xD;
&#xD;
          -  Known immunodeficiency, including Acquired Immune Deficiency Syndrome or use of&#xD;
             immunosuppressive or cancer chemotherapeutic drugs.&#xD;
&#xD;
          -  Pregnancy or breastfeeding during the study. A serum pregnancy test will be performed&#xD;
             at Screening for female patients of childbearing potential. In addition, patients who&#xD;
             are considered likely to be pregnant may be excluded at th Investigator's discretion.&#xD;
&#xD;
          -  Any condition or situation likely to cause the patient to be unable or unwilling to&#xD;
             participate in study procedures or participate in all scheduled study assessments,&#xD;
             including follow up through Month 6.&#xD;
&#xD;
          -  Any condition likely to result in the patient's death within the next 6 Months.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, would preclude the&#xD;
             patient's participation in the study.&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
&#xD;
          -  Use of intravenous heparin in previous 48 hours, thrombolytics and/or aspirin&#xD;
             containing products in the previous 10 days.&#xD;
&#xD;
          -  Non-traumatic causes of spinal cord injury (e.g. transverse myelitis, acute disc&#xD;
             herniation, etcâ€¦).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Fehlings, MD, PhD, FRCSC, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univestity Health Network, Toronto Western</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital &amp; Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Mayfield Clinic and Spine Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrooke Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bioaxonebio.com</url>
    <description>Sponsor</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed?term=mckerracher%20Fehlings</url>
    <description>Publication</description>
  </link>
  <results_reference>
    <citation>McKerracher L, Anderson KD. Analysis of recruitment and outcomes in the phase I/IIa Cethrin clinical trial for acute spinal cord injury. J Neurotrauma. 2013 Nov 1;30(21):1795-804. doi: 10.1089/neu.2013.2909. Epub 2013 Oct 1.</citation>
    <PMID>23844986</PMID>
  </results_reference>
  <results_reference>
    <citation>Fehlings MG, Theodore N, Harrop J, Maurais G, Kuntz C, Shaffrey CI, Kwon BK, Chapman J, Yee A, Tighe A, McKerracher L. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96. doi: 10.1089/neu.2011.1765.</citation>
    <PMID>21381984</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2007</study_first_posted>
  <disposition_first_submitted>March 9, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biologic drug</keyword>
  <keyword>transport sequence</keyword>
  <keyword>rho</keyword>
  <keyword>spinal cord injury</keyword>
  <keyword>paralysis</keyword>
  <keyword>paraplegia</keyword>
  <keyword>tetraplegia</keyword>
  <keyword>quadraplegia</keyword>
  <keyword>trauma</keyword>
  <keyword>nervous system</keyword>
  <keyword>fibrin sealant</keyword>
  <keyword>neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

